4odf
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4odf]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ODF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ODF FirstGlance]. <br> | <table><tr><td colspan='2'>[[4odf]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ODF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ODF FirstGlance]. <br> | ||
| - | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2U1:6-{[(2S,5R,6R)-4-[(1S)-2-(TERT-BUTYLSULFONYL)-1-CYCLOPROPYLETHYL]-6-(3-CHLOROPHENYL)-5-(4-CHLOROPHENYL)-2-METHYL-3-OXOMORPHOLIN-2-YL]METHYL}PYRIDINE-3-CARBOXYLIC+ACID'>2U1</scene>< | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2U1:6-{[(2S,5R,6R)-4-[(1S)-2-(TERT-BUTYLSULFONYL)-1-CYCLOPROPYLETHYL]-6-(3-CHLOROPHENYL)-5-(4-CHLOROPHENYL)-2-METHYL-3-OXOMORPHOLIN-2-YL]METHYL}PYRIDINE-3-CARBOXYLIC+ACID'>2U1</scene></td></tr> |
| - | <tr><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MDM2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MDM2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> |
| - | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4odf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4odf OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4odf RCSB], [http://www.ebi.ac.uk/pdbsum/4odf PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4odf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4odf OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4odf RCSB], [http://www.ebi.ac.uk/pdbsum/4odf PDBsum]</span></td></tr> |
| - | <table> | + | </table> |
== Disease == | == Disease == | ||
[[http://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN]] Note=Seems to be amplified in certain tumors (including soft tissue sarcomas, osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding. | [[http://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN]] Note=Seems to be amplified in certain tumors (including soft tissue sarcomas, osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding. | ||
| Line 24: | Line 24: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | [[Category: Human]] | ||
| - | [[Category: Huang, X | + | [[Category: Huang, X]] |
| - | [[Category: Long, A M | + | [[Category: Long, A M]] |
| - | [[Category: Shaffer, P L | + | [[Category: Shaffer, P L]] |
| - | [[Category: Yakowec, P | + | [[Category: Yakowec, P]] |
[[Category: Ligase-ligase inhibitor complex]] | [[Category: Ligase-ligase inhibitor complex]] | ||
[[Category: P53]] | [[Category: P53]] | ||
[[Category: Protein-protein interaction]] | [[Category: Protein-protein interaction]] | ||
Revision as of 08:30, 5 January 2015
Co-Crystal Structure of MDM2 with Inhibitor Compound 47
| |||||||||||
